Immunic to Participate in Investor and Scientific Conferences in May
May 6, 2024NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
May 1, 2024– Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK, May 1, 2024 – Immunic,…Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 30, 2024– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74%…Immunic to Host MS R&D Day and Participate in Investor Conferences in April
April 4, 2024NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 20, 2024– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to…Immunic to Participate in Investor and Scientific Conferences in March
March 7, 2024NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 29, 2024NEW YORK, February 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 22, 2024– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending…Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 15, 2024– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK, February 15, 2024 – Immunic,…Immunic to Participate in Investor and Scientific Conferences in February
February 1, 2024NEW YORK, February 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…